Mark Dugall

Mark Dugall

Auto-generated profile, based on publicly available information

Mark Dugall

Department of Biomedical Sciences, Irvine3 Circulation/Vascular Labs & San Valentino Vascular Screening Project, Gabriele D'Annunzio University, Chieti, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
GBGianni Belcaro
Gianni Belcaro
ALAndrea Ledda
Andrea Ledda
SHShu Hu
Shu Hu
MCMaria Rosa Cesarone
Maria Rosa Cesarone
BFBeatrice Feragalli
Beatrice Feragalli
MDMark Dugall
Mark Dugall
The beneficial effects of Greenselect Phytosome, a proprietary lecithin formulation of a caffeine-free green tea catechin extract, were evaluated in a controlled registry study on 50 asymptomatic subjects borderline for metabolic syndrome factors and with increased plasma oxidative stress. After 24 weeks of intervention, improvement in weight, blood lipid profile, and blood pressure positioned 68% of subjects in the treatment arm out of the metabolic syndrome profile, while 80% of the subjects in the control group still remained in their initial borderline disease signature. Compared to the control (lifestyle and dietary changes alone), Greenselect Phytosome was especially effective for weight/waist changes. These results highlight the relevance of addressing multiple factors involved in the development of metabolic syndrome with a pleiotropic agent capable of improving the beneficial effects of lifestyle and dietary changes and foster the attainment of a globally improved health profile.

19 September 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
GBGianni Belcaro
Gianni Belcaro
ALAndrea Ledda
Andrea Ledda
SHShu Hu
Shu Hu
MCMaria Rosa Cesarone
Maria Rosa Cesarone
BFBeatrice Feragalli
Beatrice Feragalli
MDMark Dugall
Mark Dugall
The efficacy of a standardized grape seed procyanidins extract (GSPE, Enovita) to decrease blood pressure when associated with nondrug intervention (diet and lifestyle modifications) was investigated in a controlled registry study involving 119 healthy, pre- and mildly hypertensive subjects. Two dosages of Enovita were evaluated (150 and 300 mg/die), using blood pressure and heart rate as the primary endpoints and complementing these observations with a laser Doppler flowmetry (LDF) investigation of the microcirculation state and an evaluation of the plasma oxidative status. After four months of treatment, a statistically significant higher, and dose-dependent, improvement in all endpoints was observed in the treatment groups compared to that of the control, with blood pressure normalizing in 93% of the higher dosage (300 mg) treatment group. Taken together, these observations suggest that GSPEs have beneficial cardiovascular effects that complement current intervention strategies in the hypertension area. The effect on blood pressure adds to the beneficial effects of GSPEs on the cardiovascular disease (CVD) phenotype associated with the oxidation of membrane lipids (endothelial dysfunction, formation of oxidized LDL, and activation of phagocytic cells).

1 March 2002 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
LIL. Incandela
L. Incandela
GBG. Belcaro
G. Belcaro
SRS. Renton
S. Renton
MDM. T. DeSanctis
M. T. DeSanctis
MCM. R. Cesarone
M. R. Cesarone
GAG. Acerbi
G. Acerbi
The aim of this study was to demonstrate whether HR (Paroven-Venoruton; 0-(β-hydroxyethyl)-rutosides), was effective in improving the microcirculation in venous hypertension and microangiopathy. Sixty patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis were included. After informed consent, patients were randomized into a treatment group and a placebo group. Patients in the treatment group received oral HR (2 g/day for 8 weeks); those in the placebo group received a comparable placebo. Results: The two groups were comparable for age and sex distribution. The mean age was 45 years (SD 9) in the treatment group (31 patients) and 45.5 (SD 10) in the placebo group (29 patients). There were no differences between the placebo and treatment groups at inclusion. There was no change between inclusion and measurements at 8 weeks in the placebo group. A significant decrease (P < 0.05) in flux at rest and rate of ankle swelling was observed in the treatment group. The decrease in capillary filtration was associated with improvement in signs and symptoms (P < 0.05). The difference in flux, sign and symptoms, and filtration was clinically important at 8 weeks in the treatment group when compared with the placebo group. No adverse effects were observed. Conclusion: Venous microangiopathy was improved by HR treatment.

15 March 2006
Verified
Book Chapter
Closed access
PDF file
GBGianni Belcaro
Gianni Belcaro
MCMaria Rosaria Cesarone
Maria Rosaria Cesarone
MDMark Dugall
Mark Dugall
MVMaria Giulia Vinciguerra
Maria Giulia Vinciguerra
ALAndrea Giovanni Ledda
Andrea Giovanni Ledda
BEBruno M. Errichi
Bruno M. Errichi